Thursday, September 18, 2025 3:23:37 PM
The only real hope for shorts is that the majority of the CHMP committee will not consider one p2b/p3 trial to be enough.
Heaven forbid if that were to happen but if it did with our safety, once later approved I would block that nation(s) from receiving the drug.
Recent AVXL News
- Anavex shares collapse after CHMP issues negative signal on Alzheimer’s therapy • IH Market News • 11/14/2025 01:45:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:42:01 PM
- Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease • GlobeNewswire Inc. • 11/14/2025 12:30:00 PM
- Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group • GlobeNewswire Inc. • 10/29/2025 11:30:00 AM
- Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ • GlobeNewswire Inc. • 10/10/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2025 12:42:50 AM
- Anavex shares climb on upbeat results from schizophrenia trial • IH Market News • 10/02/2025 12:45:17 PM
- Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program • GlobeNewswire Inc. • 10/02/2025 11:35:00 AM
- Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/02/2025 11:30:00 AM
- Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial • GlobeNewswire Inc. • 09/30/2025 12:30:00 PM
- Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial • GlobeNewswire Inc. • 09/09/2025 11:30:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 • GlobeNewswire Inc. • 09/02/2025 11:30:00 AM
- Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine • GlobeNewswire Inc. • 08/26/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 09:30:21 PM
- Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease • GlobeNewswire Inc. • 08/20/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2025 08:08:20 PM
- Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/12/2025 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 • GlobeNewswire Inc. • 08/05/2025 11:30:00 AM
- Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease • GlobeNewswire Inc. • 07/31/2025 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/25/2025 08:48:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/24/2025 04:15:19 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/14/2025 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 09:25:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 09:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/09/2025 09:30:47 PM
Veri Medtech (VRHI) Files Registration Statement for Proposed Initial Public Offering • VRHI • Nov 17, 2025 8:30 AM
ECGI Appoints AI Platform Architect as CTO to Build Mortgage Tokenization Infrastructure • ECGI • Nov 13, 2025 8:30 AM
Alliance Creative Group (ACGX) Releases 2025 Q3 Quarterly Financial and Disclosure Report • ACGX • Nov 13, 2025 4:40 AM
The Hidden Force Behind the AI Revolution • META • Nov 12, 2025 9:00 AM
The Clean Energy Breakthrough That Could Power the AI Era • MAXXF • Nov 12, 2025 9:00 AM
ECGI Highlights Fintech Expansion Through RezyFi Acquisition and Tokenized Mortgage Platform in Shareholder Letter • ECGI • Nov 11, 2025 8:30 AM
